Carmelo Nucera, Ph.D., M.D.
This page shows the publications co-authored by Carmelo Nucera and Sareh Parangi.
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011 Apr 01; 71(7):2417-22.
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16(3):296-309.
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget. 2010 Dec; 1(8):751-6.
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010 Jun 08; 107(23):10649-54.
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 2009 Oct; 19(10):1077-84.
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta. 2009 Apr; 1795(2):152-61.
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012 Feb; 153(2):985-94.
Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery. 2010 Dec; 148(6):1154-62; discussion 1162.
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010 Jul; 200(1):136-43.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.